BNP Paribas Financial Markets’s TherapeuticsMD TXMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $457 | Hold |
226
| – | – | ﹤0.01% | 5555 |
|
|
2025
Q4 | $368 | Hold |
226
| – | – | ﹤0.01% | 5506 |
|
|
2025
Q3 | $243 | Hold |
226
| – | – | ﹤0.01% | 5371 |
|
|
2025
Q2 | $262 | Buy |
226
+2
| +0.9% | +$2 | ﹤0.01% | 5266 |
|
|
2025
Q1 | $207 | Hold |
224
| – | – | ﹤0.01% | 5204 |
|
|
2024
Q4 | $193 | Buy |
+224
| New | +$315 | ﹤0.01% | 5234 |
|
|
2022
Q4 | – | Sell |
-311
| Closed | -$2.06K | – | 4617 |
|
|
2022
Q3 | $2.06K | Buy |
+311
| New | +$2.52K | ﹤0.01% | 4343 |
|
|
2022
Q2 | – | Sell |
-670
| Closed | -$12.7K | – | 4251 |
|
|
2022
Q1 | $12.7K | Sell |
670
-935
| -58% | -$14.7K | ﹤0.01% | 3771 |
|
|
2021
Q4 | $28.5K | Buy |
1,605
+269
| +20% | +$8.06K | ﹤0.01% | 3821 |
|
|
2021
Q3 | $49.5K | Buy |
1,336
+1,073
| +408% | +$47.6K | ﹤0.01% | 3517 |
|
|
2021
Q2 | $15.6K | Sell |
263
-870
| -77% | -$52.7K | ﹤0.01% | 3608 |
|
|
2021
Q1 | $75.9K | Sell |
1,133
-2,799
| -71% | -$219K | ﹤0.01% | 3471 |
|
|
2020
Q4 | $238K | Buy |
3,932
+2,708
| +221% | +$185K | ﹤0.01% | 2799 |
|
|
2020
Q3 | $96.7K | Buy |
1,224
+833
| +213% | +$66.4K | ﹤0.01% | 3136 |
|
|
2020
Q2 | $24.4K | Sell |
391
-1,027
| -72% | -$59.8K | ﹤0.01% | 3309 |
|
|
2020
Q1 | $75.2K | Buy |
1,418
+852
| +151% | +$84.5K | ﹤0.01% | 3350 |
|
|
2019
Q4 | $68.4K | Sell |
566
-88
| -13% | -$12.7K | ﹤0.01% | 3489 |
|
|
2019
Q3 | $119K | Buy |
654
+195
| +42% | +$27.5K | ﹤0.01% | 3039 |
|
|
2019
Q2 | $59.7K | Sell |
459
-354
| -44% | -$63.5K | ﹤0.01% | 3314 |
|
|
2019
Q1 | $198K | Buy |
813
+769
| +1,748% | +$203K | ﹤0.01% | 2712 |
|
|
2018
Q4 | $8.31K | Sell |
44
-108
| -71% | -$26.3K | ﹤0.01% | 3413 |
|
|
2018
Q3 | $49.9K | Buy |
152
+6
| +4% | +$1.84K | ﹤0.01% | 3041 |
|
|
2018
Q2 | $45.4K | Sell |
146
-548
| -79% | -$167K | ﹤0.01% | 3166 |
|
|
2018
Q1 | $169K | Sell |
694
-7
| -1% | -$1.96K | ﹤0.01% | 2895 |
|
|
2017
Q4 | $212K | Buy |
701
+366
| +109% | +$102K | ﹤0.01% | 2932 |
|
|
2017
Q3 | $88.6K | Sell |
335
-23
| -6% | -$6.65K | ﹤0.01% | 2847 |
|
|
2017
Q2 | $94.2K | Buy |
358
+317
| +773% | +$79.4K | ﹤0.01% | 2851 |
|
|
2017
Q1 | $14.9K | Sell |
41
-424
| -91% | -$131K | ﹤0.01% | 3090 |
|
|
2016
Q4 | $134K | Buy |
465
+237
| +104% | +$73.4K | ﹤0.01% | 2409 |
|
|
2016
Q3 | $77.5K | Buy |
228
+112
| +97% | +$40.9K | ﹤0.01% | 2223 |
|
|
2016
Q2 | $49.4K | Buy |
+116
| New | +$47.8K | ﹤0.01% | 2307 |
|
|
2016
Q1 | – | Sell |
-488
| Closed | -$253K | – | 3068 |
|
|
2015
Q4 | $253K | Sell |
488
-45
| -8% | -$16.6K | ﹤0.01% | 1773 |
|
|
2015
Q3 | $156K | Buy |
533
+322
| +153% | +$114K | ﹤0.01% | 2118 |
|
|
2015
Q2 | $83.1K | Buy |
211
+155
| +277% | +$54.7K | ﹤0.01% | 2184 |
|
|
2015
Q1 | $16.8K | Buy |
+56
| New | +$13.7K | ﹤0.01% | 2450 |
|
|
2014
Q4 | – | Sell |
-141
| Closed | -$32.7K | – | 3113 |
|
|
2014
Q3 | $32.7K | Buy |
141
+138
| +4,600% | +$34.8K | ﹤0.01% | 2848 |
|
|
2014
Q2 | $575 | Sell |
3
-26
| -90% | -$5.79K | ﹤0.01% | 3565 |
|
|
2014
Q1 | $6.03K | Sell |
29
-19
| -40% | -$6.05K | ﹤0.01% | 2377 |
|
|
2013
Q4 | $12.5K | Sell |
48
-454
| -90% | -$99.4K | ﹤0.01% | 2506 |
|
|
2013
Q3 | $73.5K | Sell |
502
-122
| -20% | -$14.8K | ﹤0.01% | 2468 |
|
|
2013
Q2 | $94.6K | Buy |
+624
| New | +$85.5K | ﹤0.01% | 2541 |
|
Other funds holding TXMD
RCMNY
CC
SCM
VCM
TC
ACM
BNP Paribas Financial Markets's TXMD Position: Q1 2026 in Review
BNP Paribas Financial Markets held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 226 shares worth $457. The position accounts for ﹤0.01% of the portfolio, ranked #5555.
BNP Paribas Financial Markets first reported a position in TXMD in Q2 2013 and has held it in 41 quarters since. The position peaked at $253K in Q4 2015. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.
- BNP Paribas Financial Markets held 226 shares of TherapeuticsMD worth $457 as of Q1 2026.
- BNP Paribas Financial Markets left its TherapeuticsMD share count unchanged in Q1 2026.
- TherapeuticsMD made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #5555 holding.
- BNP Paribas Financial Markets first reported a position in TherapeuticsMD in Q2 2013 and has held it in 41 quarters since.
- BNP Paribas Financial Markets's TherapeuticsMD position peaked at $253K in Q4 2015.
- 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.